New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
NCT ID NCT07622862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll 16 adults aged 18-70 to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DQ1001 (a universal allogeneic CAR-T cell therapy targeting BCMA and GPRC5D)
- What this could lead to
- If successful, this could provide a new treatment option for patients with hard-to-treat multiple myeloma, potentially improving response rates and extending survival.
- What could go wrong
- This is a very early (Phase 1) trial with only 16 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA PROGRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart resistant myeloma?
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on incurable blood cancer
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check